Top Markets
#1 MarsCoin MarsCoin +55.22%
#2 Palladium Network Palladium Network +52.93%
#3 Siren Siren +27.68%
#4 Useless Coin Useless Coin +25.64%
#5 Status Status +19.19%
#6 edgeX edgeX +18.18%
#7 Bedrock Bedrock +17.35%
#8 PondCoin PondCoin +15.89%
#9 Asteroid Shiba Asteroid Shiba +15.47%
#10 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +15.19%
Coin of the day
MarsCoin MarsCoin
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
KemPharm, Inc. KemPharm, Inc.

KemPharm, Inc.

KMPH
Peringkat dalam Saham #18404
KemPharm, Inc. operates as a specialized pharmaceutical firm focused on... KemPharm, Inc. operates as a specialized pharmaceutical firm focused on discovering and advancing proprietary prodrugs to tackle serious medical conditions across the United States. The company employs its innovative Ligand Activated Therapy (LAT) platform to create improved prodrug versions of medications already approved by the FDA, and also to develop prodrugs from existing compounds for potential applications in new disease indications. Its pipeline of investigational prodrugs strategically targets high-need areas such as attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) disorders, including idiopathic hypersomnia (IH). KP1077, KemPharm's leading experimental compound, is a prodrug of d-methylphenidate, known as serdexmethylphnidate, and is currently in Phase II clinical trials for the treatment of IH and narcolepsy. Additionally, the company is advancing KP879, a prodrug candidate designed to treat stimulant use disorder, which is undergoing Phase I clinical evaluation. KemPharm has also obtained FDA approval for AZSTARYS, a new once-daily ADHD treatment for patients aged six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen. The company holds collaboration and license agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Founded in 2006, KemPharm, Inc. is headquartered in Celebration, Florida.
Harga Saham
$5.81
Terakhir disinkronkan: 2023-02-28
Kapitalisasi Pasar
$200.14M
Perubahan (1 hari)
-0.34%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan KemPharm, Inc. (KMPH)

Kategori

Healthcare
Pendapatan untuk KemPharm, Inc. (KMPH)
Pendapatan pada Sep 2026 TTM: 0
Menurut laporan keuangan terbaru dari KemPharm, Inc., pendapatan saat ini (TTM) adalah 0. Pada tahun 2026, perusahaan menghasilkan pendapatan sebesar 0 sama dengan pendapatan pada tahun 2026 yang sebesar 0. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan KemPharm, Inc. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Pendapatan untuk perusahaan serupa atau pesaing
Perusahaan Pendapatan Perbedaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH